Last reviewed · How we verify
Jincaopian Tablets high dose — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Jincaopian Tablets high dose (Jincaopian Tablets high dose) — Beijing Konruns Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Jincaopian Tablets high dose TARGET | Jincaopian Tablets high dose | Beijing Konruns Pharmaceutical Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Jincaopian Tablets high dose CI watch — RSS
- Jincaopian Tablets high dose CI watch — Atom
- Jincaopian Tablets high dose CI watch — JSON
- Jincaopian Tablets high dose alone — RSS
Cite this brief
Drug Landscape (2026). Jincaopian Tablets high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/jincaopian-tablets-high-dose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing